nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—KCNQ3—Interaction between L1 and Ankyrins—SCN5A—dilated cardiomyopathy	0.0565	0.117	CbGpPWpGaD
Ezogabine—KCNQ2—Interaction between L1 and Ankyrins—SCN5A—dilated cardiomyopathy	0.0565	0.117	CbGpPWpGaD
Ezogabine—KCNQ5—Potassium Channels—ABCC9—dilated cardiomyopathy	0.0252	0.0521	CbGpPWpGaD
Ezogabine—KCNQ4—Potassium Channels—ABCC9—dilated cardiomyopathy	0.0252	0.0521	CbGpPWpGaD
Ezogabine—KCNQ3—L1CAM interactions—SCN5A—dilated cardiomyopathy	0.0217	0.0448	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—SCN5A—dilated cardiomyopathy	0.0217	0.0448	CbGpPWpGaD
Ezogabine—Nephrolithiasis—Furosemide—dilated cardiomyopathy	0.0176	0.0341	CcSEcCtD
Ezogabine—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.0163	0.0316	CcSEcCtD
Ezogabine—KCNQ2—Potassium Channels—ABCC9—dilated cardiomyopathy	0.0136	0.0281	CbGpPWpGaD
Ezogabine—KCNQ3—Potassium Channels—ABCC9—dilated cardiomyopathy	0.0136	0.0281	CbGpPWpGaD
Ezogabine—Memory impairment—Lisinopril—dilated cardiomyopathy	0.0135	0.0262	CcSEcCtD
Ezogabine—Alopecia—Spironolactone—dilated cardiomyopathy	0.0115	0.0223	CcSEcCtD
Ezogabine—KCNQ5—Neuronal System—ABCC9—dilated cardiomyopathy	0.011	0.0227	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—ABCC9—dilated cardiomyopathy	0.011	0.0227	CbGpPWpGaD
Ezogabine—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.0109	0.0212	CcSEcCtD
Ezogabine—KCNQ5—Neuronal System—ACTN2—dilated cardiomyopathy	0.0106	0.0218	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—ACTN2—dilated cardiomyopathy	0.0106	0.0218	CbGpPWpGaD
Ezogabine—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.0105	0.0204	CcSEcCtD
Ezogabine—Malaise—Spironolactone—dilated cardiomyopathy	0.0102	0.0198	CcSEcCtD
Ezogabine—Leukopenia—Spironolactone—dilated cardiomyopathy	0.0102	0.0197	CcSEcCtD
Ezogabine—Urinary retention—Furosemide—dilated cardiomyopathy	0.00975	0.0189	CcSEcCtD
Ezogabine—Discomfort—Spironolactone—dilated cardiomyopathy	0.00954	0.0185	CcSEcCtD
Ezogabine—Confusional state—Spironolactone—dilated cardiomyopathy	0.00934	0.0181	CcSEcCtD
Ezogabine—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00907	0.0176	CcSEcCtD
Ezogabine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00823	0.016	CcSEcCtD
Ezogabine—KCNQ3—Axon guidance—SCN5A—dilated cardiomyopathy	0.00819	0.0169	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—SCN5A—dilated cardiomyopathy	0.00819	0.0169	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00799	0.0155	CcSEcCtD
Ezogabine—KCNQ2—Developmental Biology—ZIC3—dilated cardiomyopathy	0.00772	0.0159	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—ZIC3—dilated cardiomyopathy	0.00772	0.0159	CbGpPWpGaD
Ezogabine—Diplopia—Lisinopril—dilated cardiomyopathy	0.00769	0.0149	CcSEcCtD
Ezogabine—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00769	0.0149	CcSEcCtD
Ezogabine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00763	0.0148	CcSEcCtD
Ezogabine—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00747	0.0145	CcSEcCtD
Ezogabine—UGT1A9—PPARA activates gene expression—ANKRD1—dilated cardiomyopathy	0.0072	0.0149	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ANKRD1—dilated cardiomyopathy	0.00704	0.0145	CbGpPWpGaD
Ezogabine—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.007	0.0136	CcSEcCtD
Ezogabine—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00695	0.0135	CcSEcCtD
Ezogabine—Visual impairment—Furosemide—dilated cardiomyopathy	0.00683	0.0133	CcSEcCtD
Ezogabine—Influenza—Lisinopril—dilated cardiomyopathy	0.00665	0.0129	CcSEcCtD
Ezogabine—Eye disorder—Furosemide—dilated cardiomyopathy	0.00663	0.0129	CcSEcCtD
Ezogabine—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00622	0.0121	CcSEcCtD
Ezogabine—Dysuria—Lisinopril—dilated cardiomyopathy	0.00622	0.0121	CcSEcCtD
Ezogabine—Malnutrition—Furosemide—dilated cardiomyopathy	0.00617	0.012	CcSEcCtD
Ezogabine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00612	0.0119	CcSEcCtD
Ezogabine—Weight increased—Lisinopril—dilated cardiomyopathy	0.00605	0.0117	CcSEcCtD
Ezogabine—KCNQ2—Neuronal System—ABCC9—dilated cardiomyopathy	0.00595	0.0123	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—ABCC9—dilated cardiomyopathy	0.00595	0.0123	CbGpPWpGaD
Ezogabine—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00593	0.0115	CcSEcCtD
Ezogabine—KCNQ2—Developmental Biology—SCN5A—dilated cardiomyopathy	0.00585	0.0121	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—SCN5A—dilated cardiomyopathy	0.00585	0.0121	CbGpPWpGaD
Ezogabine—Rash—Spironolactone—dilated cardiomyopathy	0.00584	0.0113	CcSEcCtD
Ezogabine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00583	0.0113	CcSEcCtD
Ezogabine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00582	0.0113	CcSEcCtD
Ezogabine—KCNQ2—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.00572	0.0118	CbGpPWpGaD
Ezogabine—KCNQ3—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.00572	0.0118	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—ACTN2—dilated cardiomyopathy	0.00571	0.0118	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—ACTN2—dilated cardiomyopathy	0.00571	0.0118	CbGpPWpGaD
Ezogabine—Haematuria—Lisinopril—dilated cardiomyopathy	0.00565	0.011	CcSEcCtD
Ezogabine—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.0056	0.0109	CcSEcCtD
Ezogabine—Vertigo—Furosemide—dilated cardiomyopathy	0.00555	0.0108	CcSEcCtD
Ezogabine—Leukopenia—Furosemide—dilated cardiomyopathy	0.00553	0.0107	CcSEcCtD
Ezogabine—Nausea—Spironolactone—dilated cardiomyopathy	0.0055	0.0107	CcSEcCtD
Ezogabine—Hallucination—Lisinopril—dilated cardiomyopathy	0.00529	0.0103	CcSEcCtD
Ezogabine—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00525	0.0102	CcSEcCtD
Ezogabine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00524	0.0102	CcSEcCtD
Ezogabine—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00522	0.0101	CcSEcCtD
Ezogabine—Dry mouth—Furosemide—dilated cardiomyopathy	0.00514	0.00997	CcSEcCtD
Ezogabine—Confusional state—Furosemide—dilated cardiomyopathy	0.00508	0.00985	CcSEcCtD
Ezogabine—Shock—Furosemide—dilated cardiomyopathy	0.00496	0.00961	CcSEcCtD
Ezogabine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00494	0.00958	CcSEcCtD
Ezogabine—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00493	0.00957	CcSEcCtD
Ezogabine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00487	0.00945	CcSEcCtD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.00485	0.01	CbGpPWpGaD
Ezogabine—Alopecia—Lisinopril—dilated cardiomyopathy	0.0047	0.00912	CcSEcCtD
Ezogabine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00466	0.00904	CcSEcCtD
Ezogabine—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00463	0.00898	CcSEcCtD
Ezogabine—KCNQ2—L1CAM interactions—RAC1—dilated cardiomyopathy	0.0046	0.00949	CbGpPWpGaD
Ezogabine—KCNQ3—L1CAM interactions—RAC1—dilated cardiomyopathy	0.0046	0.00949	CbGpPWpGaD
Ezogabine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00452	0.00877	CcSEcCtD
Ezogabine—Somnolence—Furosemide—dilated cardiomyopathy	0.00448	0.00869	CcSEcCtD
Ezogabine—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00445	0.00864	CcSEcCtD
Ezogabine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00436	0.00847	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00435	0.00844	CcSEcCtD
Ezogabine—Fatigue—Furosemide—dilated cardiomyopathy	0.00434	0.00842	CcSEcCtD
Ezogabine—Tremor—Lisinopril—dilated cardiomyopathy	0.00434	0.00842	CcSEcCtD
Ezogabine—Constipation—Furosemide—dilated cardiomyopathy	0.00431	0.00836	CcSEcCtD
Ezogabine—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.0043	0.00833	CcSEcCtD
Ezogabine—Malaise—Lisinopril—dilated cardiomyopathy	0.00418	0.0081	CcSEcCtD
Ezogabine—Vertigo—Lisinopril—dilated cardiomyopathy	0.00416	0.00807	CcSEcCtD
Ezogabine—Syncope—Lisinopril—dilated cardiomyopathy	0.00415	0.00806	CcSEcCtD
Ezogabine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00415	0.00805	CcSEcCtD
Ezogabine—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00415	0.00804	CcSEcCtD
Ezogabine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00407	0.0079	CcSEcCtD
Ezogabine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00393	0.00762	CcSEcCtD
Ezogabine—Discomfort—Lisinopril—dilated cardiomyopathy	0.0039	0.00756	CcSEcCtD
Ezogabine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00386	0.00748	CcSEcCtD
Ezogabine—Confusional state—Lisinopril—dilated cardiomyopathy	0.00381	0.00739	CcSEcCtD
Ezogabine—Infection—Lisinopril—dilated cardiomyopathy	0.00375	0.00728	CcSEcCtD
Ezogabine—Shock—Lisinopril—dilated cardiomyopathy	0.00372	0.00721	CcSEcCtD
Ezogabine—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.0037	0.00718	CcSEcCtD
Ezogabine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00365	0.00709	CcSEcCtD
Ezogabine—Asthenia—Furosemide—dilated cardiomyopathy	0.00361	0.00701	CcSEcCtD
Ezogabine—KCNQ2—Axon guidance—PSEN2—dilated cardiomyopathy	0.00345	0.00713	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—PSEN2—dilated cardiomyopathy	0.00345	0.00713	CbGpPWpGaD
Ezogabine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00339	0.00658	CcSEcCtD
Ezogabine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00337	0.00654	CcSEcCtD
Ezogabine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00336	0.00652	CcSEcCtD
Ezogabine—Dizziness—Furosemide—dilated cardiomyopathy	0.00333	0.00646	CcSEcCtD
Ezogabine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00333	0.00645	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00326	0.00633	CcSEcCtD
Ezogabine—Fatigue—Lisinopril—dilated cardiomyopathy	0.00326	0.00632	CcSEcCtD
Ezogabine—Constipation—Lisinopril—dilated cardiomyopathy	0.00323	0.00627	CcSEcCtD
Ezogabine—Rash—Furosemide—dilated cardiomyopathy	0.00318	0.00616	CcSEcCtD
Ezogabine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00317	0.00616	CcSEcCtD
Ezogabine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00311	0.00604	CcSEcCtD
Ezogabine—Nausea—Furosemide—dilated cardiomyopathy	0.00299	0.0058	CcSEcCtD
Ezogabine—Asthenia—Lisinopril—dilated cardiomyopathy	0.00271	0.00526	CcSEcCtD
Ezogabine—Dizziness—Lisinopril—dilated cardiomyopathy	0.0025	0.00485	CcSEcCtD
Ezogabine—NAT2—Metabolism—ANKRD1—dilated cardiomyopathy	0.00247	0.00511	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—PSEN2—dilated cardiomyopathy	0.00246	0.00509	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—PSEN2—dilated cardiomyopathy	0.00246	0.00509	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.00243	0.00501	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—RAF1—dilated cardiomyopathy	0.0024	0.00496	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—RAF1—dilated cardiomyopathy	0.0024	0.00496	CbGpPWpGaD
Ezogabine—Rash—Lisinopril—dilated cardiomyopathy	0.00238	0.00462	CcSEcCtD
Ezogabine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00238	0.00462	CcSEcCtD
Ezogabine—NAT2—Metabolism—TAZ—dilated cardiomyopathy	0.00233	0.0048	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.00231	0.00477	CbGpPWpGaD
Ezogabine—Nausea—Lisinopril—dilated cardiomyopathy	0.00225	0.00435	CcSEcCtD
Ezogabine—KCNQ2—Axon guidance—ITGB1—dilated cardiomyopathy	0.00216	0.00446	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—ITGB1—dilated cardiomyopathy	0.00216	0.00446	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—SDHA—dilated cardiomyopathy	0.0021	0.00434	CbGpPWpGaD
Ezogabine—KCNQ3—L1CAM interactions—EGFR—dilated cardiomyopathy	0.00209	0.00431	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—EGFR—dilated cardiomyopathy	0.00209	0.00431	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.00202	0.00416	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00193	0.00399	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.00192	0.00396	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00182	0.00375	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—RAC1—dilated cardiomyopathy	0.00174	0.00359	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—RAC1—dilated cardiomyopathy	0.00174	0.00359	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.00162	0.00334	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.00158	0.00327	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—ITGB1—dilated cardiomyopathy	0.00154	0.00318	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—ITGB1—dilated cardiomyopathy	0.00154	0.00318	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.0015	0.00309	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.00146	0.00301	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	0.00143	0.00294	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—TAZ—dilated cardiomyopathy	0.00141	0.00291	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.00139	0.00288	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.00139	0.00288	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.00133	0.00274	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.00133	0.00274	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CD36—dilated cardiomyopathy	0.00132	0.00272	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—CD36—dilated cardiomyopathy	0.00132	0.00272	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—RAF1—dilated cardiomyopathy	0.0013	0.00268	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—RAF1—dilated cardiomyopathy	0.0013	0.00268	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—SDHA—dilated cardiomyopathy	0.00127	0.00263	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ANKRD1—dilated cardiomyopathy	0.00125	0.00257	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—RAC1—dilated cardiomyopathy	0.00124	0.00256	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—RAC1—dilated cardiomyopathy	0.00124	0.00256	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TAZ—dilated cardiomyopathy	0.00117	0.00242	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—RAF1—dilated cardiomyopathy	0.00115	0.00238	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—RAF1—dilated cardiomyopathy	0.00115	0.00238	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.00109	0.00225	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SDHA—dilated cardiomyopathy	0.00106	0.00219	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.000983	0.00203	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000861	0.00178	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000861	0.00178	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—RAF1—dilated cardiomyopathy	0.000822	0.0017	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—RAF1—dilated cardiomyopathy	0.000822	0.0017	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TAZ—dilated cardiomyopathy	0.000809	0.00167	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TAZ—dilated cardiomyopathy	0.000809	0.00167	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—EGFR—dilated cardiomyopathy	0.00079	0.00163	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—EGFR—dilated cardiomyopathy	0.00079	0.00163	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SDHA—dilated cardiomyopathy	0.000732	0.00151	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SDHA—dilated cardiomyopathy	0.000732	0.00151	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000664	0.00137	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TAZ—dilated cardiomyopathy	0.000624	0.00129	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GPX1—dilated cardiomyopathy	0.000571	0.00118	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SDHA—dilated cardiomyopathy	0.000564	0.00116	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EGFR—dilated cardiomyopathy	0.000564	0.00116	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EGFR—dilated cardiomyopathy	0.000564	0.00116	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CD36—dilated cardiomyopathy	0.000556	0.00115	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TNF—dilated cardiomyopathy	0.000537	0.00111	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TNF—dilated cardiomyopathy	0.000537	0.00111	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—AGT—dilated cardiomyopathy	0.000501	0.00103	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000446	0.000922	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000435	0.000897	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000391	0.000808	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GPX1—dilated cardiomyopathy	0.000346	0.000715	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CD36—dilated cardiomyopathy	0.000337	0.000696	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—AGT—dilated cardiomyopathy	0.000304	0.000627	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GPX1—dilated cardiomyopathy	0.000288	0.000594	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CD36—dilated cardiomyopathy	0.00028	0.000578	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—AGT—dilated cardiomyopathy	0.000252	0.000521	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GPX1—dilated cardiomyopathy	0.000199	0.00041	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GPX1—dilated cardiomyopathy	0.000199	0.00041	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CD36—dilated cardiomyopathy	0.000194	0.0004	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CD36—dilated cardiomyopathy	0.000194	0.0004	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AGT—dilated cardiomyopathy	0.000174	0.00036	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AGT—dilated cardiomyopathy	0.000174	0.00036	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GPX1—dilated cardiomyopathy	0.000153	0.000316	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CD36—dilated cardiomyopathy	0.000149	0.000308	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AGT—dilated cardiomyopathy	0.000134	0.000277	CbGpPWpGaD
